Larry Biegelsen News
-
Medtronic Inc.’s aortic valve, inserted into the heart via a catheter, doesn’t violate Edwards Lifesciences Inc.’s Cribier patent, the German District Court of Mannheim ruled.
-
Medtronic Inc.’s aortic valve, inserted into the heart via a catheter, doesn’t violate Edwards Lifesciences Inc.’s Cribier patent, the German District Court of Mannheim ruled.
-
Ernest Lau, a cardiologist at the Royal Victoria Hospital in Belfast, Ireland, was one of the first doctors to identify a defect in St. Jude Medical Inc.’s Riata that led to its recall in 2011. Now Lau is telling colleagues it’s time to embrace the company’s updated device.
-
Nanostim Inc.’s miniaturized pacemaker, a device the size of a AAA battery placed entirely in the heart, appeared promising in its first human trials.
-
Boston Scientific Corp.’s study of a heart device to reduce stroke risk, slated for presentation at a medical heart meeting this weekend, is under review after the company said only limited data about the product’s safety would be released.
-
Edwards Lifesciences Corp., the maker of artificial heart valves, slid the most in 12 years after third-quarter sales were lower than the company’s forecast.
-
St. Jude Medical Inc.’s device to plug openings in the heart after a stroke failed to definitively prevent repeat incidents in patients under age 60 compared with non-surgical drug treatment, two studies found.
-
A complication that causes drug- coated heart stents to weaken and shrink will be reviewed at a medical meeting next week, researchers said.
-
Edwards Lifesciences Corp.’s Sapien device replaces damaged aortic heart valves as well as surgery, without cracking open the chest or triggering higher rates of stroke or death after two years, a company-funded study found.
-
Johnson & Johnson’s abiraterone acetate, a pill to be marketed as Zytiga, was approved by U.S. regulators for use in patients with late-stage prostate cancer who had previously received chemotherapy.
|
|
Most Popular on Bloomberg
|
| |
Rate this Page